StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultNov 4, 2026, 04:37 PM

Adaptive Biotechnologies Q3 Revenue $83.9M; Net Income $2.88M

AI Summary

Adaptive Biotechnologies Corporation filed its quarterly report for the period ending September 30, 2026. The company reported a decrease in revenue and net income for the third quarter compared to the previous year, with revenue falling to $83.9 million from $93.97 million and net income decreasing to $2.88 million from $9.55 million. However, year-to-date revenue showed an increase to $226.3 million from $205.3 million. The company also reported a significant increase in total assets and liabilities, largely due to the issuance of $335.4 million in convertible senior notes.

Key Highlights

  • Adaptive Biotechnologies reported Q3 2026 revenue of $83.9M, a decrease from $93.97M in Q3 2025.
  • Nine-month 2026 revenue was $226.3M, up from $205.3M in the same period of 2025.
  • Q3 2026 net income was $2.88M, a decrease from $9.55M in Q3 2025.
  • Nine-month 2026 net loss was $56.9M, compared to a net loss of $45.9M in the same period of 2025.
  • Total assets increased to $683.1M as of September 30, 2026, from $512.7M as of December 31, 2025.
  • Total liabilities increased to $499.2M as of September 30, 2026, from $287.7M as of December 31, 2025.
  • Issued $335.4M in convertible senior notes in the nine months ended September 30, 2026.